Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8265802 | 1.00 | ACE (0.55) | ACEMMEBACE1DPP4MEN1 | |
| SCHEMBL4797895 | 1.00 | ACE (0.55) | ACEMMEBACE1DPP4MEN1 | |
| SCHEMBL4798432 | 0.83 | BACE1 (0.41) | ACEMMEBACE1POLBMAPT | |
| SCHEMBL4798440 | 0.83 | BACE1 (0.41) | ACEMMEBACE1POLBMAPT | |
| SCHEMBL4798449 | 0.83 | BACE1 (0.41) | ACEMMEBACE1POLBMAPT | |
| SCHEMBL9252361 | 0.81 | PIK3CD (0.38) | ACEMMEBACE1DPP4POLB | |
| SCHEMBL2079186 | 0.80 | ACE (0.51) | ACEBACE1MAPTITGB3ITGA2B | |
| SCHEMBL2079182 | 0.80 | ACE (0.51) | ACEBACE1MAPTITGB3ITGA2B | |
| SCHEMBL8266792 | 0.80 | ACE (0.51) | ACEBACE1MAPTITGB3ITGA2B | |
| SCHEMBL5114366 | 0.79 | MME (0.45) | ACEMMEBACE1PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388007-B2 | Gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060046984-A1 | Novel gamma-lactams as beta-secretase inhibitors | THOMPSON LORIN A III | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046984-A1 | Novel gamma-lactams as beta-secretase inhibitors | BACE1, BACE2, APP | ACE 86/4885MME 420/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.